Cite
MLA Citation
R. Nanda et al.. “Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study.” European journal of cancer, vol. 72, n.d., pp. S38–. http://access.bl.uk/ark:/81055/vdc_100041522076.0x00005d